...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>South African medical journal: Suid-Afrikaanse tydskrif vir geneeskunde >Changes to the World Health Organization guideline on hormonal contraceptive eligibility for women at high risk of HIV: South African perspective and response
【24h】

Changes to the World Health Organization guideline on hormonal contraceptive eligibility for women at high risk of HIV: South African perspective and response

机译：艾滋病毒高危妇女荷尔蒙避孕措施对荷尔蒙避孕措施的改变：南非视角和反应

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The World Health Organization (WHO) published guidelines for hormonal contraceptive eligibility for women at high risk of HIV in March 2017. This guidance followed from a technical consultative meeting convened by the WHO in December 2016, where all the available evidence on hormonal contraceptives and risk of HIV acquisition was reviewed. This was an expert meeting with representation from global experts in family planning and HIV management, including clinicians, epidemiologists, researchers and civil society. The guideline development group, through a consensus, made recommendations to change the medical eligibility criteria for contraceptive use from category 1 to category 2 for progestogen-only injectable contraceptives among women at high risk of HIV. There was no change in the recommendation for all other methods of hormonal contraception. The data that informed this decision are from observational studies, which have limitations; therefore, causality or association of hormonal contraception and risk of HIV acquisition have not been proven. This guidance will have an impact on countries that have a high HIV disease burden and where progestogen-only injectable contraceptives are the highest used, as in South Africa (SA). The information has to be communicated in line with the WHO's sexual and reproductive health rights principles of ensuring that all women should receive evidence-based recommendations. This will empower them to make informed choices about their reproductive needs. This article seeks to clarify the decision-making process of the WHO and how the new recommendations were formulated. It also gives SAs response to the guidance and a perspective of what informed the National Department of Health's position, taking into account the effect this will have on SAs contraceptive guidelines.
机译：世界卫生组织（世卫组织）于2017年3月发表了艾滋病毒高风险的激素避孕措施的指导方针。这一指导遵循了2016年12月由世卫组织召开的技术协商会议，其中所有可用的荷尔蒙避孕药和风险的证据审查了艾滋病毒委员会。这是与全球计划生育和艾滋病毒管理层的全球专家代表的专家会议，包括临床医生，流行病学家，研究人员和民间社会。该指南开发集团通过共识，提出了改变避孕药资格使用的建议，以便在艾滋病毒的高风险中对孕激素中的孕激素可注射措施进行避孕药中的避孕药权。所有其他荷尔蒙避孕方法的建议没有变化。通知该决定的数据来自观察性研究，这些研究具有局限性;因此，尚未证明荷尔蒙避孕的因果关系或艾滋病毒收购风险的关系。这一指导将对艾滋病病毒性疾病负担的国家产生影响，并且仅在孕激素可注射避孕药是最高的，如南非（SA）。这些信息必须符合世卫组织的性和生育卫生权利原则，确保所有妇女应获得基于证据的建议。这将赋予他们对他们的生殖需求做出明智的选择。本文旨在澄清世卫组织和如何制定新建议的决策过程。它还向SAS对指导的回应提供了响应，并考虑到国家卫生局的地位，考虑到这一效果，这将对SAS避孕准则有所了解。

著录项

  • 来源
  • 作者

    Nene Z.; Hofmeyr G. J.; Patel M.; Panday M.; Rees H.; Makua M.; Pillay Y.;

  • 作者单位

    Univ Pretoria Fac Hlth Sci Dept Obstet &

    Gynaecol Reprod &

    Endocrine Unit Pretoria South Africa;

    Univ Ft Hare Fac Hlth Sci Effect Care Res Unit East London South Africa;

    Univ Cape Town Fac Hlth Sci Dept Obstet &

    Gynaecol Reprod Med Unit Cape Town South Africa;

    Univ KwaZulu Natal King Dinuzulu Hosp Complex Family Planning Dept Durban South Africa;

    Univ Witwatersrand Wits Reprod Hlth &

    HIV Inst Johannesburg South Africa;

    Natl Dept Hlth Pretoria South Africa;

    Natl Dept Hlth Pretoria South Africa;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 医药、卫生;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号